This blog will reflect on 3 things drug developers should pay attention to regarding safety when taking a new chemical entity or biologic drug into human testing.
The Simcyp PBPK Simulator is the industry leader and most widely adopted platform for PBPK modeling in drug development. Watch the demo!
Certara’s Phoenix biosimulation software platform is widely used for non-compartmental analysis (NCA), pharmacokinetic/pharmacodynamic (PK/PD), and population PK analysis. Recently, we have seen how Certara software helps customers accelerate collaboration across…
Historically, the dosing strategy for oncology drugs has focused on the maximum tolerated dose. This has resulted in drugs’ pharmacokinetic (PK) profiles, pharmacokinetic/pharmacodynamic (PK/PD) relationships, and clinical target inhibition largely…
As your company moves towards the regulatory submission of a marketing application to a health authority, there are many things to consider in your project planning. Among those is whom…
RsNLME is a collection of R packages & RShiny apps that allow scientists to run models using the Certara NLME engine directly from the R command line.
Expands software portfolio and nonclinical drug development expertise PRINCETON, N.J.— Jan 5, 2022– Certara, Inc., a global leader in biosimulation, today announced the acquisition of Integrated Nonclinical Development Solutions, Inc….
FDA holds more than 400 SimcypTM and PhoenixTM software licenses across 12 divisions and offices PRINCETON, N.J.— December 21, 2021 – Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation,…
© 2025 Certara. All Rights Reserved. | Privacy policy
